VISCOSUPPLEMENTATION MARKET ANALYSIS

Key Developments

• In September 2021, Bioventus Inc., a frontrunner in advancements for active healing, revealed that the American Academy of Orthopaedic Surgeons (AAOS) has issued revised clinical practice guidelines (CPG), highlighting that high molecular weight cross-linked hyaluronic therapies, such as Bioventus' DUROLANE, have demonstrated statistically notable enhancements in specific knee osteoarthritis (OA) cases.
• In August 2021, Seikagaku Corporation, a pharmaceutical company introduced HyLink, a single-injection viscosupplement designed for intra-articular treatment of knee osteoarthritis in Taiwan, in partnership with TCM Biotech International Corp., a biotechnology company. HyLink features a cross-linked hyaluronate hydrogel, crafted utilizing Seikagaku Corporation's distinctive crosslinking method, as its primary component.